{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:03:08Z","timestamp":1782968588287,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Tumour cells with <jats:italic>BRCA1\/2<\/jats:italic> gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AG014699, even after these cells acquired resistance to a PARP inhibitor or cisplatin.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This phase II single-arm trial investigated the activity of 6MP 55\u201375\u2009mg\/m<jats:sup>2<\/jats:sup> per day, and methotrexate 15\u201320\u2009mg\/m<jats:sup>2<\/jats:sup> per week in advanced breast or platinum-resistant ovarian cancer patients with a <jats:italic>BRCA1\/2<\/jats:italic> germline mutation, who had progressed after\u2009\u22651 previous line of chemotherapy. The primary outcome was objective response including stable disease (SD) as an assessment of clinical benefit rate (CBR), at 8 weeks, by RECIST v1.1. Secondary outcomes included overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In total, 67 evaluable patients were recruited; 55 ovarian and 11 breast cancer patients. In total, 21 patients had SD (31%), one had a partial response (1.5%); CBR was 33% at 8 weeks. In total, 12\/67 patients (18%) had SD at 16 weeks. In total, five ovarian cancer patients had SD for over 200 days. Median OS was 10.3 months (95% CI 6.9\u201314.5), median PFS 1.9 months (1.7\u20132.8).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The overall activity of 6MP and methotrexate in these patients was low; however, there was a small group of patients who appeared to derive longer-term clinical benefit.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>NCT01432145 <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ClinicalTrials.gov\">http:\/\/www.ClinicalTrials.gov<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1038\/s41416-019-0674-4","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:02:50Z","timestamp":1575849770000},"page":"483-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours"],"prefix":"10.1038","volume":"122","author":[{"given":"Corran","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Y.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Kopijasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Folkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stratford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibani","family":"Nicum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"674_CR1","unstructured":"Ferlay, J. S. I, Ervik, M, Dikshit, R, Eser, S, Mathers, C., Rebelo, M. et al. Rebelo M et al. GLOBOCAN2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, Lyon, France: International Agency for Research on Cancer. http:\/\/globocan.iarc.fr (2013)."},{"key":"674_CR2","doi-asserted-by":"crossref","first-page":"viii61","DOI":"10.1093\/annonc\/mdx443","volume":"28","author":"EA Eisenhauer","year":"2017","unstructured":"Eisenhauer, E. A. Real-world evidence in the treatment of ovarian cancer. Ann. Oncol. 28, viii61\u2013viii65 (2017).","journal-title":"Ann. Oncol."},{"key":"674_CR3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Kwan, E. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68, 700\u2013710 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"674_CR4","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654\u20132663 (2012).","journal-title":"J. Clin. Oncol."},{"key":"674_CR5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.321.7261.624","volume":"321","author":"K McPherson","year":"2000","unstructured":"McPherson, K., Steel, C. M. & Dixon, J. M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 321, 624\u2013628 (2000).","journal-title":"BMJ"},{"key":"674_CR6","first-page":"95","volume":"18","author":"D Easton","year":"1993","unstructured":"Easton, D., Ford, D. & Peto, J. Inherited susceptibility to breast cancer. Cancer Surv. 18, 95\u2013113 (1993).","journal-title":"Cancer Surv."},{"key":"674_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1677\/erc.0.0060405","volume":"6","author":"S Oesterreich","year":"1999","unstructured":"Oesterreich, S. & Fuqua, S. A. Tumor suppressor genes in breast cancer. Endocr. Relat. Cancer. 6, 405\u2013419 (1999).","journal-title":"Endocr. Relat. Cancer."},{"key":"674_CR8","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","volume":"11","author":"SR Lakhani","year":"2005","unstructured":"Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S. et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11, 5175\u20135180 (2005).","journal-title":"Clin. Cancer Res."},{"key":"674_CR9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"674_CR10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"674_CR11","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J., Huang S-yN, Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res."},{"key":"674_CR12","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","volume":"49","author":"P Polak","year":"2017","unstructured":"Polak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet. 49, 1476 (2017).","journal-title":"Nat. Genet."},{"key":"674_CR13","unstructured":"FDA. Lynparza (olaparib) tablets, for oral use: prescribing information. https:\/\/www.fda.gov\/drugs\/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients (2018)."},{"key":"674_CR14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"674_CR15","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 390, 1949\u20131961 (2017).","journal-title":"The Lancet"},{"key":"674_CR16","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"674_CR17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"674_CR18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","volume":"229","author":"LJ Barber","year":"2013","unstructured":"Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K. et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422\u2013429 (2013).","journal-title":"J. Pathol."},{"key":"674_CR19","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-16-0416","volume":"76","author":"M Makvandi","year":"2016","unstructured":"Makvandi, M., Xu, K., Lieberman, B. P., Anderson, R.-C., Effron, S. S., Winters, H. D. et al. A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP Inhibitor Therapy. Cancer Res. 76, 4516 (2016).","journal-title":"Cancer Res."},{"key":"674_CR20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E. et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535, 382 (2016).","journal-title":"Nature"},{"key":"674_CR21","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1158\/0008-5472.CAN-09-3416","volume":"70","author":"N Issaeva","year":"2010","unstructured":"Issaeva, N., Thomas, H. D., Djureinovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S. et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70, 6268\u20136276 (2010).","journal-title":"Cancer Res."},{"key":"674_CR22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10637-005-4020-8","volume":"23","author":"S Coulthard","year":"2005","unstructured":"Coulthard, S. & Hogarth, L. The thiopurines: An update. Investigational New Drugs. 23, 523\u2013532 (2005).","journal-title":"Investigational New Drugs."},{"key":"674_CR23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.273.5278.1109","volume":"273","author":"PF Swann","year":"1996","unstructured":"Swann, P. F., Waters, T. R., Moulton, D. C., Xu, Y. Z., Zheng, Q., Edwards, M. et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273, 1109\u20131111 (1996).","journal-title":"Science"},{"key":"674_CR24","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/bi00182a006","volume":"33","author":"S Griffin","year":"1994","unstructured":"Griffin, S., Branch, P., Xu, Y. Z. & Karran, P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 33, 4787\u20134793 (1994).","journal-title":"Biochemistry"},{"key":"674_CR25","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1021\/bi9621573","volume":"36","author":"TR Waters","year":"1997","unstructured":"Waters, T. R. & Swann, P. F. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry. 36, 2501\u20132506 (1997).","journal-title":"Biochemistry."},{"key":"674_CR26","first-page":"2327","volume":"9","author":"T Yan","year":"2003","unstructured":"Yan, T., Berry, S. E., Desai, A. B. & Kinsella, T. J. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells. Clin. Cancer Res. 9, 2327\u20132334 (2003).","journal-title":"Clin. Cancer Res."},{"key":"674_CR27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","volume":"43","author":"L Lennard","year":"1992","unstructured":"Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329\u2013339 (1992).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"674_CR28","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","volume":"91","author":"MV Relling","year":"1999","unstructured":"Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 91, 2001\u20132008 (1999).","journal-title":"J Natl Cancer Inst."},{"key":"674_CR29","unstructured":"Dean L. Mercaptopurine Therapy and TPMT Genotype (eds Pratt V., McLeod H., Dean L., Malheiro A. & Rubinstein W.). (Medical Genetics Summaries, Bethesda, MD, 2012)."},{"key":"674_CR30","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/0006-2952(88)90359-0","volume":"37","author":"JP Bokkerink","year":"1988","unstructured":"Bokkerink, J. P., De Abreu, R. A., Bakker, M. A., Hulscher, T. W., van Baal, J. M., Schretlen, E. D. et al. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem. Pharmacol. 37, 2329\u20132338 (1988).","journal-title":"Biochem. Pharmacol."},{"key":"674_CR31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/emmm.200900040","volume":"1","author":"SA Martin","year":"2009","unstructured":"Martin, S. A., McCarthy, A., Barber, L. J., Burgess, D. J., Parry, S., Lord, C. J. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 1, 323\u2013337 (2009).","journal-title":"EMBO Mol. Med."},{"key":"674_CR32","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-983","volume":"14","author":"S Nicum","year":"2014","unstructured":"Nicum, S., Roberts, C., Boyle, L., Kopijasz, S., Gourley, C., Hall, M. et al. A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer 14, 983 (2014).","journal-title":"BMC Cancer"},{"key":"674_CR33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0197-2456(01)00142-8","volume":"22","author":"SH Jung","year":"2001","unstructured":"Jung, S. H., Carey, M. & Kim, K. M. Graphical search for two-stage designs for phase II clinical trials. Control Clin. Trials. 22, 367\u2013372 (2001).","journal-title":"Control Clin. Trials."},{"key":"674_CR34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/sim.1600","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung, S. H., Lee, T., Kim, K. & George, S. L. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 23, 561\u2013569 (2004).","journal-title":"Stat Med."},{"key":"674_CR35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpba.2008.10.045","volume":"49","author":"AF Hawwa","year":"2009","unstructured":"Hawwa, A. F., Millership, J. S., Collier, P. S. & McElnay, J. C. Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells. J. Pharm. Biomed. Anal. 49, 401\u2013409 (2009).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"674_CR36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmana, J. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J. Clin. Oncol. 33, 244\u2013250 (2015).","journal-title":"J. Clin. Oncol."},{"key":"674_CR37","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdu363","volume":"25","author":"IA McNeish","year":"2014","unstructured":"McNeish, I. A., Ledermann, J. A., Webber, L., James, L., Kaye, S. B., Hall, M. et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancerdagger. Ann. Oncol. 25, 1988\u20131995 (2014).","journal-title":"Ann. Oncol."},{"key":"674_CR38","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ejca.2012.11.016","volume":"49","author":"DS Tan","year":"2013","unstructured":"Tan, D. S., Yap, T. A., Hutka, M., Roxburgh, P., Ang, J., Banerjee, S. et al. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eu.r J. Cancer 49, 1246\u20131253 (2013).","journal-title":"Eu.r J. Cancer"},{"key":"674_CR39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","volume":"30","author":"SB Kaye","year":"2012","unstructured":"Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y. et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30, 372\u2013379 (2012).","journal-title":"J. Clin. Oncol."},{"key":"674_CR40","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0140-6736(94)92400-7","volume":"343","author":"JS Lilleyman","year":"1994","unstructured":"Lilleyman, J. S. & Lennard, L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 343, 1188\u20131190 (1994).","journal-title":"Lancet."},{"key":"674_CR41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2008.03281.x","volume":"66","author":"AF Hawwa","year":"2008","unstructured":"Hawwa, A. F., Collier, P. S., Millership, J. S., McCarthy, A., Dempsey, S., Cairns, C. et al. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br. J. Clin. Pharmacol. 66, 826\u2013837 (2008).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"674_CR42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc1800","volume":"6","author":"MH Cheok","year":"2006","unstructured":"Cheok, M. H. & Evans, W. E. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 6, 117\u2013129 (2006).","journal-title":"Nat Rev Cancer."},{"key":"674_CR43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","volume":"118","author":"JF Colombel","year":"2000","unstructured":"Colombel, J. F., Ferrari, N., Debuysere, H., Marteau, P., Gendre, J. P., Bonaz, B. et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn\u2019s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 118, 1025\u20131030 (2000).","journal-title":"Gastroenterology."},{"key":"674_CR44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.1996.tb00021.x","volume":"42","author":"L Lennard","year":"1996","unstructured":"Lennard, L., Welch, J. & Lilleyman, J. S. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites. Br. J. Clin. Pharmacol. 42, 525\u2013527 (1996).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"674_CR45","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2002-02-0495","volume":"100","author":"T Dervieux","year":"2002","unstructured":"Dervieux, T., Brenner, T. L., Hon, Y. Y., Zhou, Y., Hancock, M. L., Sandlund, J. T. et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 100, 1240\u20131247 (2002).","journal-title":"Blood."},{"key":"674_CR46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/modpathol.2011.211","volume":"25","author":"JN McAlpine","year":"2012","unstructured":"McAlpine, J. N., Porter, H., Kobel, M., Nelson, B. H., Prentice, L. M., Kalloger, S. E. et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod. Pathol. 25, 740\u2013750 (2012).","journal-title":"Mod. Pathol."},{"key":"674_CR47","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F. et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587\u201313598 (2016).","journal-title":"Oncotarget"},{"key":"674_CR48","doi-asserted-by":"crossref","unstructured":"Nolan, E., Savas, P., Policheni, A. N., Darcy, P. K., Vaillant, F., Mintoff, C. P., et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci. Transl. Med. 9, pii: eaal4922 (2017).","DOI":"10.1126\/scitranslmed.aal4922"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0674-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0674-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0674-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:06:23Z","timestamp":1684616783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0674-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,18]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0674-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"29 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The appropriate ethical guidelines and legislation were observed in conducting the 6MP study; namely, the study complied with the ethical principles of the Declaration of Helsinki (1996) and the regulatory requirements for clinical trials of an IMP under the European Union Clinical Trials Directive. Subjects provided their informed consent to participate in the study. The study was approved by the National Research Ethics Committee South Central\u2013Oxford B (REC reference 10\/H0605\/79).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The datasets used and\/or analysed during this study are available from the corresponding author on reasonable request with permission of 6MP trial management group committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"S.N. has received honoraria from AstraZeneca, Tesaro, Clovis and Roche and has provided consultancy for AstraZeneca, Clovis, Tesaro and Roch, and has received research funding from AstraZeneca. C.G. has received honoraria from AstraZeneca, Tesaro, Cor2Ed and Medscape; has provided consultancy for AstraZeneca, Clovis, Nucana, Tesaro, Roche, Foundation One and Cor2Ed; his institution receives research funding from AstraZeneca, Aprea AB, Nucana and Tesaro. R.K. receives payment as medical director for Almac Diagnostics. J.A. has received honorarium in the past 24 months, which has included travel expenses for advisory roles from Novartis and Genomic Health. S.B. has received research funding from Astrazeneca and has served on advisory boards for Astrazeneca, Tesaro and Clovis. All other authors jointly declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was sponsored by the University of Oxford, with funding from Cancer Research UK\u2019s Clinical Trials Award and Advisory Committee (CTAAC) who approved a full funding application on 26th October 2010 (grant no: C1488\/A12447), and this work was supported by the Oxford Partnership Comprehensive Biomedical Research Centre with funding from the Department of Health\u2019s National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. VS was funded by Cancer Research UK (grant no. C5527\/A16895).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}